Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of VRDN is 40 and suggests 42% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell